Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen, has struck a fresh biosimilars deal with Biogen that will give the firm marketing rights to two of Samsung Bioepis’ biosimilar candidates, ranibizumab and aflibercept, that are currently in pre-clinical and clinical development.
Samsung Bioepis Adds To Biogen Collaboration
New Deal Covers ‘Next-Generation’ Biosimilars Ranibizumab And Aflibercept
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
